BR112023008490A2 - Variantes de anticorpo bovino - Google Patents

Variantes de anticorpo bovino

Info

Publication number
BR112023008490A2
BR112023008490A2 BR112023008490A BR112023008490A BR112023008490A2 BR 112023008490 A2 BR112023008490 A2 BR 112023008490A2 BR 112023008490 A BR112023008490 A BR 112023008490A BR 112023008490 A BR112023008490 A BR 112023008490A BR 112023008490 A2 BR112023008490 A2 BR 112023008490A2
Authority
BR
Brazil
Prior art keywords
bovine antibody
antibody variants
bovine
relates
variants
Prior art date
Application number
BR112023008490A
Other languages
English (en)
Portuguese (pt)
Inventor
Pogacsas Ruhland Bally Alexander
J Strietzel Catherine
John Fici Gregory
Luis CAMPOS Henry
Prajna Shanbhogue
Ann Marie Lightle Sandra
Yaqi Zhu
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of BR112023008490A2 publication Critical patent/BR112023008490A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112023008490A 2020-11-20 2021-11-19 Variantes de anticorpo bovino BR112023008490A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063116491P 2020-11-20 2020-11-20
PCT/US2021/060161 WO2022109313A1 (en) 2020-11-20 2021-11-19 Bovine antibody variants

Publications (1)

Publication Number Publication Date
BR112023008490A2 true BR112023008490A2 (pt) 2023-12-12

Family

ID=79018979

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023008490A BR112023008490A2 (pt) 2020-11-20 2021-11-19 Variantes de anticorpo bovino

Country Status (12)

Country Link
US (1) US20230416410A1 (https=)
EP (1) EP4247851A1 (https=)
JP (1) JP2023551194A (https=)
KR (1) KR20230110297A (https=)
CN (1) CN116615463A (https=)
AR (1) AR124130A1 (https=)
AU (1) AU2021382704A1 (https=)
BR (1) BR112023008490A2 (https=)
CA (1) CA3202089A1 (https=)
CO (1) CO2023007146A2 (https=)
MX (1) MX2023005896A (https=)
WO (1) WO2022109313A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4255933A4 (en) 2020-12-07 2025-07-23 Invetx Inc COMPOSITIONS FOR INCREASING THE HALF-LIFE OF A THERAPEUTIC AGENT IN LIVESTOCK ANIMALS AND METHODS OF USE
CN119730881A (zh) * 2022-08-05 2025-03-28 硕腾服务有限责任公司 牛抗体突变体
JP2025529206A (ja) * 2022-09-02 2025-09-04 ゾエティス・サービシーズ・エルエルシー 豚抗体変異体
CN119735654B (zh) * 2025-02-27 2025-07-01 浙江海隆生物科技股份有限公司 一种牛副流感病毒的亚单位hn蛋白制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
AU2005285347A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
ES2984405T3 (es) * 2012-09-13 2024-10-29 Bristol Myers Squibb Co Proteínas de dominio de andamio basadas en fibronectina que se unen a la miostatina
US11891440B2 (en) * 2015-10-05 2024-02-06 Circle33 Llc Antibodies with improved stability to intestinal digestion, polynucleotides thereof and methods of use thereof to treat disease

Also Published As

Publication number Publication date
KR20230110297A (ko) 2023-07-21
AR124130A1 (es) 2023-02-15
AU2021382704A9 (en) 2025-03-27
WO2022109313A1 (en) 2022-05-27
MX2023005896A (es) 2023-07-03
CO2023007146A2 (es) 2023-06-30
CA3202089A1 (en) 2022-05-27
JP2023551194A (ja) 2023-12-07
CN116615463A (zh) 2023-08-18
US20230416410A1 (en) 2023-12-28
AU2021382704A1 (en) 2023-06-08
EP4247851A1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
BR112023008490A2 (pt) Variantes de anticorpo bovino
CO2022014695A2 (es) Variantes de anticuerpos caninos
BR112018067525A2 (pt) anticorpos tendo especificidade para o btla e seus usos
BR112021008873A8 (pt) Formulação
ECSP22080858A (es) Variantes de anticuerpos felinos
CO2023007829A2 (es) Mutaciones en regiones constantes de anticuerpos felinos
BR112017008945A2 (pt) Anticorpos anti-cs1 e conjugados fármaco- anticorpo
CL2024001562A1 (es) Mutaciones en regiones constantes de anticuerpos caninos.
BR112015021134A2 (pt) conjugados de fármaco e anticorpo
BR112023021867A2 (pt) Composições de anticorpo anti-tslp e seus usos
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2024000628A1 (es) Variantes de anticuerpos caninos (div 202300878; )
JOP20230239A1 (ar) أجسام مضادة للنكتين-4 واستخدامتها
UY4796S (es) Recipiente para bebidas
UY4794S (es) Recipiente para bebidas
BR112021016924A2 (pt) Oligossacarídeos do leite humano para uso no aprimoramento da função executiva
ECSP14000502A (es) Composiciones nutricionales de caseína-suero parcialmente hidrolizadas para reducir la aparición de alergias
AR087094A1 (es) Formulaciones que estabilizan proteinas
CL2024000789A1 (es) Variantes de anticuerpos felinos.
TWD200665S (zh) 智慧型手錶
MX2020007105A (es) Formulaciones de espora de nutriente y usos de las mismas.
CO2025013047A2 (es) Conjugados de anticuerpo dll3-fármaco y usos de estos
GT201200244A (es) Procedimiento de activación y conjugación de biomoléculas
BR112021018611A2 (pt) Anticorpos tendo especificidade para btn2 e usos dos mesmos
PH12020550653A1 (en) Synthetic nutritional compositions tailored for infants of specific ages, and nutritional systems comprising them